Our findings confirm such association with the detection of HR-HPV in 14/34 (41.2%) WLHA with CD4 <500 cells/mL (p = 0.002), while HR-HPV was detected in only 10/72 (13.9%) of those presenting with a CD4 cell count ≥500 cells/mL, suggesting that WLHA with CD4 <500 should remain under close surveillance for cervical cancer. This evidence concerns the gene CD4 and cervical carcinoma.